CD19 ε-TRuC

CD19 ε-TRuC (also known as TC-110) is an autologous T cell receptor engineered T cell therapy designed to treat B-cell malignancies. It consists of T cells transduced with a T cell receptor fusion construct (TRuC) comprising an anti-CD19 single-chain variable fragment (scFv), derived from the FMC63 clone, fused to the extracellular N-terminus of the CD3ε subunit of the endogenous T cell receptor (TCR) complex. Unlike traditional chimeric antigen receptors (CARs) which utilize isolated signaling domains (such as CD3ζ) and exogenous co-stimulatory domains, the TRuC integrates into the complete TCR complex, harnessing all six subunits (α, β, γ, δ, ε, and ζ) for signaling. This physiological signaling approach is intended to provide potent anti-tumor efficacy with a more controlled cytokine release profile and reduced T cell exhaustion compared to traditional second-generation CAR-T therapies. The drug was primarily developed for B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).

Other names

CD19-specific TRuC-T cellsCD-19-specific TRuC-T cellsCD 19-specific TRuC-T cellsCD19-targeting T cell receptor fusion constructCD-19-targeting T cell receptor fusion constructCD 19-targeting T cell receptor fusion constructCD19 epsilon-TRuCCD-19 epsilon-TRuCCD 19 epsilon-TRuC